This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation. X. Long Zheng, MD, PhD: What is acquired TTP? TTP ...

Thrombotic microangiopathy due to thrombotic thrombocytopenia should be suspected in a patient with otherwise unexplained thrombocytopenia and anemia, even without fever, renal dysfunction or ...

This page lists all known medications that could potentially lead to 'Thrombotic thrombocytopenic purpura' as a side effect. It's important to note that mild side effects are quite common with ...

Please provide your email address to receive an email when new articles are posted on . In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and ...

The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Adzynma, the first recombinant protein product indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in ...

Orexigenic and cytoprotective effects of a novel adenosine-enriched peptide nucleic acid compound: Implications for clinical application No significant financial relationships to disclose. This is an ...

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

THE observation of a newborn infant with widespread petechiae and thrombocytopenia born to a mother who had had rubella during the 1964 epidemic stimulated us to seek other newborn and older children ...

Researchers from the Second Affiliated Hospital of Nanjing Medical University, et al. have published a case report entitled "Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover ...

This report describes a newborn who presented with hyperbilirubinemia and thrombocytopenia. The patient recovered after treatment with antibiotics, phototherapy, and a platelet transfusion. Analysis ...